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Summary Background: Individuals with underlying cell-mediated immunodeﬁciency
disorders are at high risk of developing severe, life-threatening illness associated with
varicella-zoster virus infection. A live-attenuated varicella vaccine is recommended
for routine childhood immunisation in some countries. In healthy children, the vaccine
is efﬁcacious and safe but because immunocompromised individuals may be unable
to limit replication of live-attenuated vaccine viruses, the varicella vaccine is not
recommended for them and there are few exceptions.
Objectives: The purpose of this paper is to review the published studies address-
ing the use of the varicella vaccine in people with cell-mediated immunodeﬁciency
disorders.
Methods: A computerised search on the PubMed database was used to collect the
relevant papers published up to March 2003.
Results: The varicella vaccine has been extensively studied in susceptible children
with acute lymphoblastic leukaemia in remission, but studies involving individuals
with other immunodeﬁciency disorders are scarce. Some of the current recommen-
dations are based on very few and small studies with short follow-up. Immunocompro-
mised individuals should be given the varicella vaccine only with complete knowledge
of their clinical and immunological conditions and after considering the risks of nat-
ural infection and vaccination.
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Introduction
The varicella-zoster virus (VZV) causes two clini-
cal diseases: primary VZV infection is manifested
by varicella (chickenpox) after which the virus es-
tablishes latency in dorsal root ganglia. As a result
of waning cell-mediated immunity, VZV may reac-
tivate years or decades later causing herpes zoster
(shingles).
Varicella is predominantly a disease of child-
hood. In most temperate countries, more than 90%
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of cases of varicella occur in persons under 15
years of age.1 Serologic studies have shown that
more than 90% of adults are immune to VZV.1 There
are suggestions of higher rates of susceptibility to
VZV amongst adults in tropical areas.1 In Brazil,
a seroprevalence study showed that 57% of chil-
dren aged under 5 years, 86% of those from six to
ten years and 95% of adolescents and adults were
seropositive to VZV.2
Varicella is highly contagious. Secondary attack
rates greater than 85% amongst susceptible chil-
dren after household or close exposure have been
reported.3,4 Secondary familial cases of varicella
are usually more severe than primary cases.3
The great majority of primary VZV infection
involves uncomplicated chickenpox in otherwise
healthy children. However, severe illness with vis-
ceral involvement, mainly pneumonia, hepatitis
and encephalitis, and fatal outcome may occur.
Children less than one year of age, adults and im-
munocompromised individuals, particularly those
with impairment of cell-mediated immunity, are at
high risk for developing complications.5—12
Approximately 15—20% of the general population
will experience reactivation of VZV during their
lifetime.1,5,6 The elderly and patients with under-
lying immunodeﬁciency disorders are at increased
risk of reactivation of latent viruses. Immunocom-
promised individuals are also at higher risk of de-
veloping complications, such as multidermatomal
and visceral involvement, and recurrences of her-
pes zoster.1,5
Immunosuppressive chemotherapy is being in-
creasingly used, more intense immunosuppression
is given to patients and immunocompromised in-
dividuals are living longer. Paralleling this rise in
the number of iatrogenically immunosuppressed
patients, there is an increasing number of per-
sons infected with HIV, leading to an increase in
the number of individuals at risk of developing
severe illness if they contract VZV infection. VZV
illnesses in patients with immunodeﬁciency dis-
orders require admission to hospital and the use
of antiviral drugs. Moreover, exposure to varicella
often results in suspension or delay of scheduled
chemotherapy in susceptible persons with malig-
nant disorders and transplant recipients, increasing
the risk of progression of underlying disease or graft
rejection.9,12 The socioeconomic consequences of
VZV disease in immunocompromised patients are
catastrophic.
Administering the varicella vaccine to the healthy
susceptible siblings of immunodepressed children
has been shown to be a safe and effective strategy
to indirectly protect high-risk children by decreas-
ing their household exposure to VZV.13,14 Never-
theless, community-acquired varicella remains a
source of infection for immunocompromised indi-
viduals.
Passive immunisation with varicella zoster-
immunoglobulin (VZIG), administered within three
days of exposure, is effective in preventing dis-
ease or in reducing severity of illness in susceptible
immunocompromised persons.1,8 However, this ap-
proach requires recognition of the exposure and
needs to be repeated after each exposure. About
half of the cases of varicella amongst immun-
odepressed children occur without a recognised
exposure to VZV, and both severe and fatal vari-
cella has been documented despite appropriate
immunoprophylaxis with VZIG.8,15 Furthermore,
VZIG is expensive and in increasingly short supply.
These limitations make passive immunisation a less
than optimum strategy for preventing chickenpox.
Permanent protection provided by administering
the vaccine to the high-risk susceptible persons
themselves would be preferable.
The varicella vaccine
A live-attenuated varicella vaccine (Oka strain) was
developed in Japan in 197416 and was ﬁrst licensed
for use in high-risk children in some European coun-
tries (1984), in Japan (1987) and in Korea (1988).1
It was licensed for use in healthy children in Japan
and Korea in 1989, in the USA, Sweden and Germany
in 1995, and in Canada, in 1998.1,6
A single dose of the vaccine (≥1000 plaque
forming units—PFU/0.5mL) results in seroconver-
sion in 95% of healthy children.5,6 The efﬁcacy of
the vaccine is about 70—90% in preventing chick-
enpox and 95—100% in protecting against severe
illness.5,6,17,18 The vaccine is less immunogenic
in healthy adolescents and adults, hence the rec-
ommendation of administering two doses, four to
eight weeks apart, to persons aged over 12 years.1
The varicella vaccine induces both humoral and
cell-mediated immune responses.16,19 Mean an-
tibody titers are usually lower after vaccination
than after natural VZV infection.1 Antibody titers
have been observed to increase over time af-
ter immunisation, presumably due to sub-clinical
re-exposure to the wild-type virus or endogenous
reactivation.1,20 Japanese studies have shown that
immunity to varicella following vaccination lasts
for at least ten to 20 years.16,19,21 However, in
Japan, vaccination against varicella is optional and
the vaccine coverage is low (<20%) allowing circu-
lation of the wild-type virus.16,19,21 There are con-
cerns about the duration of immunity induced by
the vaccine without being boosted by re-exposure
to the wild-type virus.16,19
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The vaccine is safe and well tolerated in healthy
individuals. The most common adverse effects are
reactions at the injection site (pain, swelling, red-
ness and rash) observed in 7—30% of vaccinees.1,5,17
The frequency of fever varies from 0—36%.17 A
generalised mild varicella-like rash was reported
in approximately 5% of vaccinees.4,17,18 Post-licen-
sure studies found that most adverse effects were
mild.22,23 Serious adverse events were rare and the
role of the vaccine-strain virus was not conﬁrmed
for the great majority of them.22,23
The World Health Organization recommends con-
sidering routine childhood immunisation against
varicella in countries where the disease is an im-
portant public health and socioeconomic issue,
where the vaccine is affordable and where high
(from 85—95%) and sustained vaccine coverage can
be achieved.5 In Brazil, routine childhood immu-
nisation against varicella is not currently feasible,
considering its high costs and other public health
priorities.24 In the USA and Canada, the vaccine
is recommended for all children aged 12 to 18
months and for susceptible older children, adoles-
cents and adults.1,6 In the USA, the introduction
of the varicella vaccine to the routine childhood
immunisation program has already been followed
by a reduction in the incidence of varicella in both
vaccinated and unvaccinated children in areas with
moderate vaccine coverage, suggesting a herd pro-
tection effect.25,26
Although the vaccine is highly protective and
safe, and routine childhood immunisation against
VZV seems to be cost-effective,17—19 there are ob-
stacles to universal immunisation. There is a per-
ception that varicella is a mild disease in healthy
children and concerns that the efﬁcacy of the vac-
cine could wane, in case of no re-exposure to VZV,
leading to a shift in the epidemiology of the dis-
ease with an increase in the number of cases of
chickenpox in adolescents and adults.27
Varicella vaccine coverage rates vary greatly
over the USA and the persistence of areas with low
vaccine coverage creates the potential for circula-
tion of the wild-type virus,25,26 Furthermore, how
the varicella vaccination will affect the incidence
of herpes zoster is not yet clear. Exposure to vari-
cella can boost speciﬁc VZV immunity, reducing the
risks of reactivation.28 Mathematical models pre-
dict that the incidence of varicella would rapidly
decline following the implementation of routine
immunisation,28,29 but ‘the loss of exogenous
boosting resulting from the decline in varicella in-
cidence could cause an increase in the incidence of
shingles in short to medium term. This increase in
incidence of zoster is likely to continue for a num-
ber of decades. The more effective the programme
is at reducing the incidence of varicella, then the
larger the increase in the incidence of zoster’.29
In places where universal childhood immunisation
against varicella has been adopted, administering
the vaccine to the majority of the susceptible pop-
ulation, including immunocompromised persons, is
critical to decrease the circulation of the wild-type
virus. In resource-poor countries, where the inci-
dence of varicella is high and routine administra-
tion of the varicella vaccine for all children is not
viable, targeted vaccination may be a strategy to
protect high-risk individuals from severe disease,
even though no impact on the epidemiology of the
infection is expected.4,29
Immunocompromised persons may be unable to
limit replication of live-attenuated vaccine viruses
resulting in life-threatening vaccine-induced ill-
ness. Severe varicella with visceral involvement
caused by the vaccine-strain virus has been occa-
sionally reported in intensely immunodepressed
subjects who were inadvertently vaccinated.30,31
The ability of the varicella vaccine-strain virus
to establish latency and reactivate16 complicates
even more its use in individuals with immunodeﬁ-
ciency disorders. Currently, the varicella vaccine
may be given to persons with impaired humoral
immunity.27,32 However, because of the risks of
administering a live-attenuated vaccine to in-
dividuals with underlying cell-mediated immun-
odeﬁciency disorders, the vaccine is not recom-
mended for them, with few exceptions.1,24,27,32—35
(Table 1).
Objectives
The aim of this review is to discuss the method-
ological aspects and results of published studies
referring to the use of the varicella vaccine in
persons with underlying cell-mediated immunod-
eﬁciency disorders. Based on that, the recom-
mendations that may already be made for these
individuals and which studies are required to
develop better knowledge in this area will be
evaluated.
Methods
The relevant papers published up to March 2003
were collected through a computerised search on
the PubMed database using the keywords ‘varicella
vaccine’. There was no language restriction. The
search was carried out on 21 January 2003, and
repeated on 8 April 2003. Of the 866 items found,
only 91 papers referring to the use of the vaccine in
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Table 1 Current recommendations for administering varicella vaccine to individuals with underlying immunode-
ﬁciency disorders.
Patient population Reference
Children with impaired humoral immunity. 27,32
Patients with acute lymphoblastic leukemia (ALL) who: 1,24,27,33
are 12 months to 17 years of age
have a negative history of varicella
have leukaemia in remission for at least 12 months
have a peripheral blood lymphocyte count ≥700 cells/mm3
have a platelet count of ≥100,000/mm3 within 24 hours of vaccination are not being
submitted to radiotherapy;
chemotherapy should be withheld for seven days before and after immunisation.
Bone marrow transplant recipients who: 33
are immunocompetent
are not receiving immunosuppressant drugs;
do not have graft versus host disease two years or more after the transplant.
Children and susceptible adolescents and adults in chronic dialysis. 34
Candidates for solid organ transplantation who are susceptible to VZV at least three
weeks before grafting.
24
Children who have conditions that require systemic steroid therapy: 1
if they are receiving <2mg/kg of body weight or a total of 20mg/day of prednisone
or its equivalent
those who are receiving high doses of systemic steroids (≥2mg/kg prednisone) for
≥two weeks may be vaccinated after steroid therapy has been discontinued for at
least three months.
Susceptible subjects that will be submitted for chemotherapy (in clinical trials). 24
HIV-infected children: 24,27,32,35
in CDC class N1 or A1*
with age-speciﬁc CD4 T lymphocyte count ≥25%32 or ≥20%.35.
HIV-infected susceptible adults and adolescents: 24,35
without clinical signs of immunodeﬁciency
with CD4 T lymphocyte count of ≥20%.
* In CDC’s paediatric HIV classiﬁcation system, Class 1 is an immunologic category deﬁned as ‘no evidence of
immunodeﬁciency’. Two clinical categories under Class 1 are considered: N1 is deﬁned as ‘no signs or symptoms’,
and A1 is deﬁned as ‘mild signs or symptoms’.
individuals with underlying cell-mediated immun-
odeﬁciency disorders (leukaemias, solid tumours,
chronic liver disease, end-stage renal failure, bone
marrow or solid organ transplantation, HIV infec-
tion, and use of corticosteroids) were retained.
Randomised controlled trials, open-label trials, co-
hort studies, reviews, and case reports of adverse
effects were selected. Letters (four) were ex-
cluded. Additionally, post-licensure adverse events
reports (two) and guidelines and recommenda-
tions for immunisation against varicella from the
World Health Organization, the Centers for Disease
Control and Prevention, the American Academy
of Pediatrics, Health Canada (National Advisory
Committee on Immunization), and the Ministry of
Health of Brazil were included.
Clinical trials involving individuals with
underlying immunodeﬁciency disorders
The live-attenuated varicella vaccine has been ex-
tensively studied in susceptible children with acute
lymphoblastic leukaemia (ALL), but studies involv-
ing individuals with other immunodeﬁciency disor-
ders such as solid tumours, bone marrow and solid
organ transplantation, end-stage renal failure,
chronic liver disease, conditions requiring chronic
steroid therapy and HIV infection are limited.
Very few randomised controlled trials were con-
ducted in these individuals. Considering prior evi-
dence of the vaccine efﬁcacy in healthy children,
placebo-controlled randomised trials involving
immunodepressed individuals would not be eth-
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ically acceptable.15,36 Additionally, taking into
account the severity of varicella in persons with im-
paired cell-mediated immunity and the efﬁcacy of
the passive immunisation with VZIG in preventing
or attenuating the disease, the recommendation of
administering VZIG after a recognised exposure to
VZV would have to be adopted if part of the study
population had received a placebo. In this case, a
very large sample size would be necessary to dis-
tinguish the effects of the vaccine itself from the
effects of VZIG, and that would make studies very
difﬁcult.
Evidence for administering the varicella vaccine
to immunocompromised subjects is based mainly
on open-label trials without internal controls. The
studies took advantage of the high attack rates of
varicella in susceptible persons after close expo-
sure to VZV that allowed the analysis of the vaccine
efﬁcacy based on comparison with historical data.
Serological methods have been used as a sur-
rogate measure of the efﬁcacy of the vaccine, as
well as to detect waning immunity over time after
vaccination. In healthy children, antibody titers
measured by an ELISA assay that detects antibodies
to VZV glycoprotein (gp-ELISA) has been strongly
correlated with protection against varicella. Chil-
dren who had post-vaccination gp-ELISA titers ≥5U
subsequently had lower incidence of varicella than
those who had post-vaccination gp-ELISA titers
<5U.37 When varicella developed in children with
post-vaccination gp-ELISA ≥5U, it was milder than
illness in children with post-vaccination gp-ELISA
<5U.37 However, different serological tests (ELISA,
IFA (indirect ﬂuorescent antibody) and FAMA (ﬂu-
orescence antibody to membrane antigen)) with
different sensitivity and speciﬁcity were used to
measure post-vaccination anti-VZV antibodies in
clinical trials. Not all these tests have been evalu-
ated as predictors of protection against varicella.
Furthermore, amongst children with malignancies,
serologic evidence of immunity may be falsely reas-
suring. There are reports of varicella in seropositive
children who underwent organ transplantation.11
On the other hand, failure to detect antibodies
against VZV does not necessarily imply susceptibil-
ity, since cell-mediated immunity may be intact.
Finally, susceptibility to VZV reactivation is related
to declining T-cell immunity against VZV but not to
low titers of anti-VZV IgG antibodies.4,10 Tests of
cell-mediated immunity are not readily available
in clinical practice and were applied in very few
trials of the varicella vaccine.
To evaluate the vaccine efﬁcacy by the rates of
breakthrough varicella, studies with large sample
size and long follow-up are required. However,
most trials involving immunocompromised individ-
uals were small and had short follow-up. In this
case, only seroconversion was used as a measure
of vaccine efﬁcacy.
Children with acute lymphoblastic leukemia
(ALL) and other malignancies
Children with acute lymphoblastic leukemia (ALL)
have been the most extensively studied im-
munocompromised group. By the end of 1983,
Japanese trials had involved 326 children with
ALL.16,19,21,38—49 A multi-centre trial conducted
between 1980 and 1992 in the USA and Canada,
by the National Institute of Allergy and Infectious
Diseases (NIAID) Varicella Vaccine Collaborative
Study Group, involving 575 children provided the
best evidence that supports the recommendations
of administering the varicella vaccine to these
individuals.36,50—61 Many other small open-label tri-
als have been conducted around the world.62—78 In
total more than 1200 children with ALL were given
the live-attenuated varicella vaccine in open-label
trials.
In children with ALL in remission who were no
longer receiving immunosuppressant drugs or for
whom maintenance chemotherapy was suspended
for at least one week before and one week after
immunisation, the vaccine has been shown to be
safe and protective. Seroconversion rates after one
dose of the vaccine varied greatly (from 42—96%)
and were, in general, smaller than those observed
in trials involving healthy children.36 Waning im-
munity over time after one dose of the vaccine has
also been demonstrated,69—71,74 suggesting that
two-dose regimens are necessary in this popula-
tion. After two doses of vaccine, seroconversion
rates were similar to those observed in healthy
children (from 85—100%).60,61,72,73 VZV-speciﬁc
cell-mediated immunity after vaccination was
demonstrated in patients with malignancies.79
In the NIAID study, the vaccine efﬁcacy estimated
by the degree of protection after household expo-
sure to varicella was 86% in protecting from disease
and 100% in protecting from severe illness.60 Data
from other studies corroborate this high grade of
protection after close exposure.16,21,62,63,66,71,72
The frequency of adverse effects, particu-
larly of varicella-like illness, has been somewhat
higher than that observed in healthy children. In
Japanese trials, the frequency of rash was greater
in children with leukaemia in remission who had
been vaccinated without suspension of mainte-
nance chemotherapy (47%) than in those for whom
chemotherapy had been withheld before and af-
ter vaccination (18.3%).16,49 In the NIAID study,
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rash related to the vaccine was more frequent
and extensive in children for whom maintenance
immunosuppressant drugs had been suspended for
immunisation (50%) than in those who had com-
pleted chemotherapy before vaccination (5%).53,60
Steroid therapy in the week before or in the week
following vaccination has been associated with ex-
tensive vaccine-induced rashes.56 Rashes were less
frequent after the second dose of the vaccine.61
Restriction enzyme analysis of DNA from virus iso-
lates showed that rashes appearing one to six weeks
after vaccination were due to the vaccine-strain
virus, whereas late rashes (more than six weeks
after vaccination) were related to the wild-type
VZV.53,65
Although most of the adverse reactions to the
vaccine were mild, severe varicella-like illness
with visceral involvement (hepatitis and pneumo-
nia) has been occasionally reported in leukaemic
children.65,70,71,80 The Oka vaccine-strain virus
was isolated from some of these patients.70,80 All
children recovered and acyclovir, when used, was
helpful.65,70,80
No differences in relapses of ALL were observed
between vaccinees and non-vaccinated children16
or those who had natural VZV infection.60
The spread of vaccine-strain virus to suscep-
tible contacts occurred only when the vaccinee
presented a skin rash.52,53,65,81 In the NIAID study,
among susceptible household contacts of leukaemic
children who had a vaccine-associated-rash, 14%
(10/74) seroconverted, and rash was observed in
seven of ten.52,53 In another study, two of seven sus-
ceptible contacts seroconverted.65 Contact cases
were mild and tertiary spread of the vaccine-strain
virus was registered just once.60
The long-term duration of immunity after
two-dose regimens still needs to be determined.
In the NIAID study, 13% of vaccinees who had ini-
tially seroconverted became seronegative over a
follow-up of up to 11 years,60 even though the
incidence and severity of breakthrough varicella
did not increase over time.55,60 Cell-mediated im-
munity against VZV was detected in three of four
patients with malignancies who had initially sero-
converted after vaccination and lost detectable
anti-VZV antibodies.79
Prospective cohort studies showed that chil-
dren with leukaemia who had been given the
varicella vaccine were less likely to develop her-
pes zoster than those who had had natural VZV
infection.16,38,58,64 In Japanese trials, herpes zoster
occurred earlier in leukaemic children who had
been naturally infected with VZV than in those
who had been vaccinated.21 Moreover, the rates of
zoster seemed to be lower in those children with
leukaemia in remission for whom maintenance
chemotherapy was suspended before and after vac-
cination (3.8%) than in those vaccinated without
suspension of immunosuppressant drugs (7.4%).21
In the NIAID study, the relative risk of herpes
zoster was greater in vaccinees who had developed
a VZV rash after vaccination (either caused by the
vaccine-strain virus or by the wild-type virus) in
comparison to those who had never had a rash
(RR = 5.75, 95% CI, 1.3 to 25.7).58 A Kaplan-Meier
life-table analysis showed that the rate of herpes
zoster in leukaemic children who had been given
more than one dose of the vaccine was lower than
in children who received just one dose.59 House-
hold exposure to VZV after vaccination was also
protective against herpes zoster.59 Finally, from
548 children with ALL who had been given the
varicella vaccine in the NIAID trial, 21 eventually
received a bone marrow transplant; herpes zoster
was observed in 14% (3/21) of transplanted chil-
dren and in 1.9% (10/527) of those who had not
been transplanted.58 Both wild-type VZV53 and
vaccine-strain virus53,82 have been isolated from
herpes zoster lesions in children with leukaemia
who had been vaccinated.
Very few children with malignancies other than
ALL were included in trials.66—70,73,77,78,83,84 In a
Japanese study, a child with lymphosarcoma de-
veloped a varicella-like illness after vaccination.61
Moreover, eight of 20 children with lymphoma who
were given the vaccine developed rashes and in
four of them the rash was severe. After that, chil-
dren with lymphoma and lymphosarcoma were not
included in clinical trials.61 Children with other
solid tumours who were given the vaccine have
not had greater frequency or severity of adverse
effects.83,84 Further studies involving patients with
solid tumours are necessary.
The great majority of studies included only chil-
drenwith leukaemia and othermalignant conditions
in remission. This approach has been safe and efﬁ-
cient in protecting children who might later suffer
a relapse of their underlying illness, even though
susceptible children are not protected against vari-
cella during the most intense induction phase of
immunosuppressive therapy, when the morbidity of
VZV infection is expected to be greater. One at-
tempt to vaccinate leukaemic children during the
induction phase of chemotherapy was catastrophic:
three of four children developed rash with fever
and one of them had visceral involvement (hep-
atitis and encephalopathy).49 However, in another
small study, the vaccine was administered to chil-
dren with cancer on the ﬁrst day of chemotherapy
with promising results.78 Seroconversion or an in-
crease in the titers of VZV antibodies occurred in
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most of the vaccinees and only four of 13 seronega-
tive children had mild adverse reactions to the vac-
cine (fever and/or rash).78 This strategy may lead
to early immunity protecting these high-risk chil-
dren soon after the diagnosis of cancer and deserves
further studies.
Most studies involving patients with malignant
disorders were conducted during the late 1970s and
early 1980s. Because current chemotherapy is likely
to be more intensely immunosuppressive than the
one used in those days, it is prudent to withhold
chemotherapy at least one week before and one
week after vaccination.60
There are small studies evaluating the use of
the vaccine in susceptible high-risk children af-
ter nosocomial exposure to varicella that showed
prevention or attenuation of the disease when the
vaccine was administered one to ﬁve days after
exposure.45—48 Although passive prophylaxis with
VZIG is more appropriate in the case of an im-
munocompromised person with known exposure to
VZV, the vaccine may be useful when VZIG is not
available.
Bone marrow transplant (BMT) recipients
The live-attenuated varicella vaccine is contraindi-
cated for bone marrow transplant (BMT) recipients
within 24 months after grafting.85 The use of the
vaccine is restricted to research protocols for pa-
tients ≥24 months after BMT who are presumed
immunocompetent.85
There is just one small study examining the use of
the live-attenuated varicella vaccine in recipients
of BMT who were no longer receiving immunosup-
pressive therapy.86 Fifteen children were given one
dose of the vaccine (2000 PFU) 12 to 23 months af-
ter BMT. No adverse reaction was observed. Eight of
nine seronegative children seroconverted and a rise
in antibody titers was observed in three of six chil-
dren with low antibody titers prior to immunisation.
Antibodies persisted for at least 24 months in six
of the eight who had seroconverted.86 None of the
vaccinees developed varicella or herpes zoster dur-
ing the 24-month follow-up period, whereas 24.1%
(32/133) of retrospectively reviewed BMT recipi-
ents who had not been immunised developed herpes
zoster within a period of 32 months after grafting.
There were three cases of disseminated zoster and
three recurrences among the historical controls.86
Further research is needed to determine the safety,
immunogenicity, and efﬁcacy of the live-attenuated
varicella vaccine in BMT recipients.
Protecting BMT recipients from VZV disease is
a particular challenge, since illness is usually due
to reactivation of latent viruses rather than to
new exposure and most diseases occur within the
ﬁrst year post-transplantation when patients are
severely immunosuppressed.10,87 Reconstitution
of VZV immunity is delayed for months and often
does not occur until after the patient experiences
a reactivation of latent viruses.87
An investigational heat-inactivated whole-virus
varicella vaccine (Oka-strain live-attenuated vari-
cella vaccine killed by heat) was evaluated in re-
cipients of BMT who were seropositive to VZV in
two small randomised controlled trials (vaccine or
no intervention).87,88 When given to BMT adults
one month after grafting, a single dose of the inac-
tivated vaccine induced VZV-speciﬁc cell-mediated
immunity, even though no clinical effects were
seen.87 In a three-dose regimen (one, two and
three months post-transplantation), the vaccine
reduced the severity of herpes zoster in vaccinees
as compared to subjects who did not receive the
intervention.87 In adults with lymphoma who re-
ceived BMT, a four-dose regimen, in which the ﬁrst
dose was given 30 days before transplantation and
three doses were given after grafting (at 30, 60 and
90 days), the inactivated vaccine signiﬁcantly re-
duced the risk of herpes zoster that was observed
in 13% (7/53) of vaccinees and in 33% (19/58) of
unvaccinated patients.88 The vaccine was well
tolerated.87,88 The inactivated varicella vaccine
may be useful for early reconstitution of speciﬁc
VZV immunity after hematopoietic transplantation,
but further studies are needed.
Patients with chronic kidney and liver
disease, and solid organ transplantation
Experience with the varicella vaccine is largely
limited to susceptible children and adolescents
with chronic renal failure and chronic liver dis-
ease prior to organ transplantation.89—98 For these
patients the live-attenuated vaccine adminis-
tered in both single and two-dose regimens (from
1000 to 2000 PFU/dose) seems to be effective and
safe.89—98
Seroconversion rates ranged from 50% to 95% af-
ter one dose of the vaccine, and from 73.5% to 100%
after two-dose regimens.89—98 Adverse events were
no more frequent or serious than those observed in
healthy children. In centres where the vaccine was
administered before solid organ transplantation, a
decrease in the incidence of both varicella and her-
pes zoster post-transplant was observed; this is in
comparison to incidents in historical controls.90
Declining titers of anti-VZV antibodies over time
after grafting has been observed in children with
chronic liver or kidney disease who had been
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immunised before transplantation.90,97 Individu-
als who had been transplanted after immunisation
tended to have lower antibody titers in the ﬁrst two
years after grafting than those who had not under-
gone transplantation.94 However, no differences
between the two groups were observed 30 months
after grafting, suggesting that the decrease in VZV
antibody levels post-transplant is transient.94 In
another study, seven liver transplant recipients,
who had been vaccinated prior to transplantation
and presented waning immunity after grafting,
were given a second dose of the vaccine one year
post-transplantation.97 No adverse effects were
observed and 57% presented an increase in anti-
body titers after re-vaccination.97 However, the
incidence of breakthrough varicella over time af-
ter vaccination was not evaluated in these studies.
Further studies are necessary to evaluate whether
booster doses of the vaccine are needed to keep
protection against VZV illnesses after solid organ
transplantation.
Just one study evaluated the vaccine in suscep-
tible children who had already received kidney
transplantation.91 In an open-label trial, one dose
of the vaccine was given to 17 transplant recipients
who were seronegative to VZV, without modiﬁca-
tion of the immunosuppressive therapy.91 No dif-
ferences in seroconversion rates and in frequency
of adverse reactions to the vaccine were observed
between transplant recipients and patients with
end-stage renal disease on chronic haemodialysis.91
Further trials are required before varicella vac-
cine is routinely administered to recipients of solid
organ transplantation.
Considering that varicella in organ transplant
recipients may be life-threatening and concerns
about decreased immunogenicity and increased
risks of live vaccines in the post-transplantation
period, most experts recommend vaccinating
susceptible patients prior to grafting wherever
possible.35,99—101 The targeted immunisation of
children before kidney or liver transplantation
seems to be a cost-effective strategy.15,102 A sur-
vey of paediatric nephrologists published in 1997,
soon after the vaccine was licensed, showed that
over 70% of them recommend varicella vaccination
for patients on dialysis or with renal failure.103
Children with steroid-sensitive nephrotic
syndrome
The experience is limited to open-label clini-
cal trials involving children with steroid-sensitive
nephrotic syndrome in remission, who were taking
low-dose steroid therapy (<2mg/kg/day, maxi-
mum 40mg of prednisone) or for whom corticos-
teroids were suspended one or two weeks before
vaccination.16,104—106 In this very controlled situ-
ation, the vaccine seems to be immunogenic and
well tolerated. Seroconversion rates after two
doses of vaccine (from 85—100%) were similar to
those observed in healthy children. Adverse re-
actions were no more frequent than in healthy
children.16,104—106 Relapse of nephrotic syndrome
following vaccination was observed,105,106 but be-
cause the studies were uncontrolled and involved
a small sample size, it is not clear whether these
relapses were related to immunisation or occurred
by chance.106
Neither the long-term duration of immunity, nor
the rate of herpes zoster in vaccinees was evalu-
ated in these studies, since all of them had short
follow-up (up to two years).
HIV infection
There is evidence that natural varicella in HIV-
seropositive children does not affect progression of
HIV infection107,108 suggesting that immunisation
of HIV-infected children against varicella is unlikely
to worsen their HIV infection.108
Just one small open-label clinical trial has
been published suggesting that the vaccine may
be safe in asymptomatic or mildly symptomatic
HIV-infected children, even though it seems to be
less immunogenic than it is in healthy children.109
Two doses of the vaccine (≥1350 PFU) were ad-
ministered to 41 susceptible HIV-infected children
in CDC class N1 or A1 at the time of immunisa-
tion. In CDC’s paediatric HIV classiﬁcation system,
Class 1 is an immunologic category deﬁned as ‘no
evidence of immunodeﬁciency’. Two clinical cate-
gories under Class 1 are considered: N1 is deﬁned
as ‘no signs or symptoms’, and A1 is deﬁned as
’mild signs or symptoms’. Seroconversion occurred
in 53% and 60% of vaccinees after one and two
doses, respectively.109 Local reactions (observed in
20% of vaccinees after the ﬁrst dose) and systemic
reactions to the vaccine (in 37%) were mild. Rash
related to the vaccine occurred only twice after
the ﬁrst dose and once after the second dose. A
marginally signiﬁcant fall in CD4 T lymphocytes
and a signiﬁcant increase in HIV viral load were ob-
served at four weeks after the ﬁrst dose of vaccine,
but no signiﬁcant effect was seen at eight weeks.109
The duration of immunity following vaccination,
as well as the rates of breakthrough varicella and
herpes zoster has not yet been evaluated.
On the other hand, there is a report of severe
illness with rash, pneumonia and polyradiculopa-
thy caused by the vaccine-strain varicella virus in a
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previously undiagnosed HIV-infected child who pre-
sented clinical category B3 and absolute CD4 T cell
count of 8 cells/mm3 at the time of diagnosis,31 sug-
gesting a potential risk of vaccinating HIV-infected
children with more advanced T-cell dysfunction.
Even considering the limited data on the use
of the vaccine in this population, the American
Academy of Pediatrics and CDC27,32 recommend
considering the varicella vaccine for HIV-infected
children in CDC class N1 or A1, with age-speciﬁc
CD4 T lymphocyte count ≥25%, after weighting po-
tential risks and beneﬁts, since HIV-infected chil-
dren are at high risk of developing severe illness
related to VZV infection.
Conclusions and future studies
Immunocompromised individuals should be vacci-
nated with the live-attenuated varicella vaccine
only with a complete knowledge of their clinical
and immunological condition as well as their thera-
peutic regimen, and after considering the relative
risks of the VZV natural infection and vaccination.
Some of the current recommendations are based
on a few small studies with short follow-up. It is nec-
essary to extend the knowledge of the safety and ef-
ﬁcacy of the vaccine in patients with solid tumours,
pre- and post-organ transplantation, with HIV infec-
tion and conditions that require chronic use of cor-
ticosteroids. The long-term safety and efﬁcacy of
varicella vaccine in high-risk individuals still need
to be determined and require continued monitor-
ing of breakthrough varicella and herpes zoster in
immunocompromised vaccinees.
Administering the varicella vaccine to immuno-
compromised persons with latent VZV infection
represents a potential strategy for preventing or
at least reducing the severity of herpes zoster in
these high-risk individuals. Immunisation with high
doses of the live-attenuated vaccine (≥3000 PFU)
was shown to be safe and to boost cell-mediated
immunity against VZV in healthy persons aged ≥55
with a previous history of varicella.110,111 Amongst
healthy elderly subjects who were followed up for
six years, it appears that the incidence of herpes
zoster was not reduced by vaccination but the re-
ported episodes of zoster were atypically mild.112
An investigational heat-inactivated vaccine seems
to be equally effective in boosting cell-mediated
immunity in elderly persons.113 The role of the
vaccine in preventing or attenuating VZV reactiva-
tion in immunocompromised individuals remains an
unexplored ﬁeld.
If routine childhood immunisation against vari-
cella results in a decreased incidence of chick-
enpox, re-evaluation of vaccination programs for
immunocompromised patients will be necessary.
There may be less need to protect VZV seronega-
tive immunocompromised individuals against vari-
cella, since the risks of exposure to the wild-type
virus will be reduced. However, booster doses of
the varicella vaccine may be needed to protect
immunodepressed persons who are seropositive to
VZV (either after vaccination or natural infection)
from developing herpes zoster.
It is desirable to provide protection to suscepti-
ble immunocompromised individuals as early as it
is safe. The investigational heat-inactivated vari-
cella vaccine might be useful for early immunisa-
tion of severely immunodepressed subjects without
the risks of administering a live-attenuated virus
vaccine to these individuals, but further studies are
necessary.
Conﬂict of Interest: No conﬂicting interest de-
clared.
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